Business Wire

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today ...
mskcc.org

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT)

Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
Business Wire

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...

Tumor bacteria linked to immunotherapy resistance in head and neck cancer

Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why ...

CRISPR cuts gene from head and neck cancers through direct injection—50% of tumors eliminated in animal models

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...
Medscape

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...